Community-acquired pneumonia: Management controversies, part 1

Journal of Respiratory Diseases

Volumn 23, Issue 1, 2002, Pages 10-28

  Niederman, Michael S ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CLARITHROMYCIN; DOXYCYCLINE; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN;

ANTIBIOTIC THERAPY; ARTICLE; DIAGNOSTIC TEST; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; INFECTION RISK; MEDICAL SOCIETY; MICROBIOLOGICAL EXAMINATION; MORBIDITY; MORTALITY; PATIENT CODING; PENICILLIN RESISTANCE; PNEUMONIA; PRACTICE GUIDELINE; UNITED STATES;

EID: 0036154233     PISSN: 0194259X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. The cost of treating community-acquired pneumonia
2. Risk factors for community-acquired pneumonia diagnosed by general practitioners for the community
3. A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women
4. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
5. Guidelines for the management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, antimicrobial therapy, and prevention
6. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies
7. Community-acquired pneumonia in adults: Guidelines for management
8. Practice guidelines for the management of community-acquired pneumonia in adults
9. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group
10. Treatment of community-acquired pneumonia
11. Community-acquired pneumonia: Impact of immune status
12. Prognosis and outcomes of patients with community-acquired pneumonia
13. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: An interventional trial
14. Applying a prediction rule to identify low-risk patients with community-acquired pneumonia
15. Community-acquired pneumonia: Development of a bedside predictive model and scoring system to identify the etiology
16. Quality of care, process, and outcomes in elderly patients with pneumonia
17. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia
18. Antimicrobial treatment failures in patients with community-acquired pneumonia: Causes and prognostic implications
19. A comparison of induced and expectorated sputum for the microbiological diagnosis of community-acquired pneumonia
20. Epidemiology of community-acquired pneumonia in adults: A population-based study
21. Multiple pathogens in adult patients admitted with community-acquired pneumonia: A one year prospective study of 346 consecutive patients
22. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio
23. Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course
24. Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes
25. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: A comparison between chlamydial and pneumococcal pneumonia
26. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia